ArticleAnnals of medicine and surgery (2012)2026
Occult hepatitis B: the masked driver of portal hypertension and life-threatening variceal hemorrhage.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and importance: Occult hepatitis B infection (OBI), characterized by undetectable hepatitis B surface antigen (HBsAg) but detectable HBV DNA, is an underrecognized contributor to chronic liver injury and portal hypertension. Portal hypertension (PHT) commonly complicates chronic liver disease, often in the setting of cirrhosis, and can lead to life-threatening variceal hemorrhage without typical biochemical or imaging abnormalities. Case Presentation: We report a case of a 30-year-old Bangladeshi male with acute upper gastrointestinal bleeding and esophageal varices in the setting of occult HBV infection. The patient lacked classical risk factors for hepatitis B, and initial viral serology was negative for HBsAg and anti-HBc. However, HBV DNA testing later confirmed occult infection. Liver ultrasound was unremarkable, showing no signs of cirrhosis or focal lesions. The patient was managed successfully with supportive care, propranolol, and multiple sessions of EVL. Acute bleeding was controlled by blood transfusion and intravenous fluid resuscitation. Endoscopic variceal ligation sessions were performed to prevent rebleeding. During follow-up, varices remained stable without further bleeding. The patient is under ongoing surveillance for portal hypertension complications. Conclusion: OBI is a hidden cause of portal hypertension and variceal bleeding. HBV DNA testing is essential in patients with portal hypertension and negative serology. Prompt EVL and vigilant follow-up are critical to preventing fatal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.